{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002172","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.739278+00:00","generated_at":"2026-06-19T21:35:41.123701+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Syndax adopts 2023 Inducement Plan, reserving 1.9M shares for new-hire equity grants","bullets":["Board approved 2023 Inducement Plan on Feb 2, 2023, under Nasdaq Rule 5635(c)(4) for inducement grants.","Plan reserves 1.9M shares of common stock for issuance to new employees as material inducement to employment.","Plan is substantially similar to 2015 Omnibus Incentive Plan but prohibits incentive stock options.","Grants require approval by a majority of Independent Directors or Independent Compensation Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002172","json":"https://secwatch.observer/filing/0000950170-23-002172.json","markdown":"https://secwatch.observer/filing/0000950170-23-002172.md","text":"https://secwatch.observer/filing/0000950170-23-002172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023002172/0000950170-23-002172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023002172/sndx-20230202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:35:41.123701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}